FSSAI suspends Dior Pharmaceuticals’ food licence over Punjab plant violations

What to watch

• FSSAI notice details, including whether the suspension is limited to the Punjab facility or affects specific products, categories or the company-wide licence.
• Timing and outcome of reinspection, corrective-action acceptance and licence restoration.
• Any recall, stop-sale, adverse-event report, product testing failure or enforcement escalation.
• Retailer and distributor delistings, order cancellations, substitution by competitors and changes in payment terms.
• Evidence of alternate production approval or inventory availability that limits stockouts.
• Whether regulators inspect additional Dior facilities or expand scrutiny across the nutraceutical sector.
• Initiate plant-wide corrective and preventive action plan covering GMP, sanitation, hazard controls, batch documentation and end-to-end traceability.
• Engage FSSAI promptly on a remediation timeline, third-party audit evidence and reinspection requirements.
• Assess finished-goods inventory, batches in distribution and any need for voluntary holds, testing or recalls.
• Secure alternate manufacturing or contract-production capacity where permitted to protect key SKUs and customers.
• Communicate supply status and quality-assurance actions to distributors, retailers and major institutional buyers.
• Ring-fence cash for remediation, potential penalties, inventory write-downs and customer claims.